---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-039777"
form_type: "8-K"
ticker: "PCVX"
cik: "0001649094"
company_name: "Vaxcyte, Inc."
filed_at: "2023-08-08T23:59:59+00:00"
generated_at: "2026-06-12T02:11:43.292017+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Vaxcyte reports Q2 net loss $68.3M, cash $1.44B, VAX-24 infant Phase 2 advanced to Stage 2

## Summary
- Cash $1.44B as of June 30, includes $545M net from April public offering.
- Net loss $68.3M for Q2 2023 vs $48.5M in Q2 2022; R&D expenses $72.7M.
- VAX-24 infant Phase 2 advanced to final stage; topline primary data expected by 2025.
- VAX-24 adult Phase 2 positive; Phase 3 topline data expected 2025; VAX-31 IND clearance expected Q4 2023.
- Board member Michael Kamarck passed away in July 2023.

## SEC filing metadata
- accession: 0000950170-23-039777
- form_type: 8-K
- ticker: PCVX
- cik: 0001649094
- company_name: Vaxcyte, Inc.
- filed_at: 2023-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649094/000095017023039777/0000950170-23-039777-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649094/000095017023039777/pcvx-20230808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-039777
- JSON: https://secwatch.observer/filing/0000950170-23-039777.json
- Plain text: https://secwatch.observer/filing/0000950170-23-039777.txt

## Key facts
- Earnings Releases
  Vaxcyte, Inc. reported financial results for the second quarter ended June 30, 2023.
  - Period: the second quarter ended June 30, 2023
  - Result: reported results
  source text: On August 8, 2023, Vaxcyte, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649094/000095017023039777/0000950170-23-039777-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.